Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

por Scherer, Daniel J, Nicholls, Stephen J
Publicado 2015

Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond

por Di Bartolo, Belinda A., Scherer, Daniel J., Nicholls, Stephen J.
Publicado 2016

Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy

por Stokes, Michael B., Thoi, Fiona, Scherer, Daniel J., Win, Kyi T. H., Kaye, David M., Teo, Karen S., Sanders, Prashanthan
Publicado 2022

Tackling cardiometabolic risk in the Asia Pacific region

por Li, Jian-Jun, Yeo, Khung Keong, Tan, Kathyrn, Ako, Junya, Krittayaphong, Rungroj, Tan, Ru San, Aylward, Philip E., Lam, CarolynS.P., Baek, Sang Hong, Dalal, Jamshed, Fong, Alan, Li, Yi-Heng, O’Brien, Richard C., Koh, Si Ya Natalie, Scherer, Daniel J., Tada, Hayato, Kang, Vernon, Butters, Julie, Nicholls, Stephen J.
Publicado 2020

Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in the Asia-Pacific Region

por Tada, Hayato, Yeo, Khung Keong, Li, Jian-Jun, Tan, Kathryn, Ako, Junya, Krittayaphong, Rungroj, San Tan, Ru, Aylward, Philip E., Lam, Carolyn S.P., Baek, Sang Hong, Dalal, Jamshed, Fong, Alan, Li, Yi-Heng, O’Brien, Richard C., Natalie Koh, Si Ya, Scherer, Daniel J., Kang, Vernon, Nelson, Adam J., Butters, Julie, Nicholls, Stephen J.
Publicado 2021